keyword
MENU ▼
Read by QxMD icon Read
search

direct acting antiviral

keyword
https://www.readbyqxmd.com/read/29040989/hepatocellular-carcinoma-after-achievement-of-sustained-viral-response-with-daclatasvir-and-asunaprevir-in-patients-with-chronic-hepatitis-c-virus-infection
#1
Hiroshi Ida, Satoru Hagiwara, Masashi Kono, Tomohiro Minami, Hirokazu Chishina, Tadaaki Arizumi, Masahiro Takita, Norihisa Yada, Yasunori Minami, Kazuomi Ueshima, Naoshi Nishida, Masatoshi Kudo
BACKGROUND: Interferon-based antiviral therapies against hepatitis C virus (HCV) infection have been shown to reduce the incidence of hepatocellular carcinoma (HCC) in patients with sustained viral response (SVR). Recently, direct-acting antivirals (DAAs) have been proven to be much more effective in achieving SVR than interferon-based therapies. However, whether DAAs can efficiently prevent the occurrence of HCC after SVR remains controversial. To clarify this issue, we analyzed the clinical features of patients in whom HCC developed after achievement of SVR with DAAs for chronic HCV infection...
2017: Digestive Diseases
https://www.readbyqxmd.com/read/29040988/unique-characteristics-associated-with-sustained-liver-damage-in-chronic-hepatitis-c-patients-treated-with-direct-acting-antivirals
#2
Masashi Kono, Naoshi Nishida, Satoru Hagiwara, Tomohiro Minami, Hirokazu Chishina, Tadaaki Arizumi, Kosuke Minaga, Ken Kamata, Yoriaki Komeda, Toshiharu Sakurai, Mamoru Takenaka, Masahiro Takita, Norihisa Yada, Hiroshi Ida, Yasunori Minami, Kazuomi Ueshima, Tomohiro Watanabe, Masatoshi Kudo
BACKGROUND AND AIMS: Direct-acting antivirals (DAAs) dramatically improve the sustained virological response (SVR) of chronic hepatitis C (CHC) patients. However, continuous liver damage after SVR may be a risk of hepatocellular carcinoma (HCC). We clarified pretreatment characteristics related to sustained liver damage after SVR. METHODS: A total of 286 CHC patients were treated with an interferon-free DAA regimen. Among them, 250 patients achieved SVR for 12 weeks after the end of treatment (SVR12); these individuals were classified based on α-fetoprotein (AFP) and alanine transaminase (ALT) levels posttreatment...
2017: Digestive Diseases
https://www.readbyqxmd.com/read/29024739/direct-antiviral-agents-daas-a-new-age-in-the-treatment-of-hepatitis-c-virus-infection
#3
REVIEW
Ulrich Spengler
Hepatitis C virus (HCV) is a global health problem, because infection frequently leads to chronic hepatitis C eventually progressing to liver cirrhosis and liver cancer. Improved insights into the HCV replication cycle and the role of HCV non-structural proteins has recently enabled to identify drugs directly acting on specific HCV target structures. Agents from three drug classes have been developed and approved by the health authorities. Combinations of two or more drugs from different classes achieve high (>90%) HCV clearance rates and are well tolerated...
October 9, 2017: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29023920/the-rise-of-the-opioid-epidemic-and-hepatitis-c-positive-organs-a-new-era-in-liver-transplantation
#4
REVIEW
Stevan A Gonzalez, James F Trotter
The use of hepatitis C virus (HCV) positive organs in liver transplantation has increased in the era of direct-acting antiviral therapy. A rising demand for organs, the ability to effectively treat HCV infection in the transplant setting, and an unprecedented increase in HCV positive donors have all contributed to this trend. A recent abrupt rise in opioid use in the US has resulted in a surge of injection drug use, transmission of HCV, and opioid-related overdose deaths. Geographic areas most affected by the opioid epidemic have experienced a rapid increase in recovery and utilization of HCV positive donor organs, in which the proportion of deceased donor liver transplants in the US from donors who are HCV positive has increased nearly two-fold within the last three years...
October 10, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29020359/sofosbuvir-based-interferon-free-direct-acting-antiviral-regimens-for-heart-transplant-recipients-with-chronic-hepatitis-c-virus-infection
#5
Chen-Hua Liu, Yih-Sharng Chen, Sheoi-Shen Wang, Chun-Jen Liu, Tung-Hung Su, Hung-Chih Yang, Chun-Ming Hong, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao
We assessed the effectiveness and safety of sofosbuvir (SOF) combined with ledipasvir (LDV) or daclatasvir (DCV) in 12 heart transplant recipients with chronic hepatitis C virus (HCV). The sustained virologic response (SVR12) rate was 100% [95% CI: 75.8%-100%]. All patients tolerated treatment well without interruption, death or serious adverse events.
September 4, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29020275/citius-altius-fortius-the-new-paradigm-in-the-treatment-of-chronic-hepatitis-c-disease
#6
George M Abraham, Linda M Spooner
With the advent of the direct-acting antiviral agents (DAAs) for chronic hepatitis C infection, the treatment paradigm has dramatically changed, especially the duration, tolerability and response to therapy. The DAAs fall into several classes and are variously indicated in the treatment of one or more genotypes of infection. All these agents are orally administered, and they are largely renally eliminated (with exceptions), don't require adjustment in mild to moderate renal insufficiency. Most of these agents demonstrate a high barrier to resistance and are extremely well-tolerated by patients...
August 21, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29020156/idsa-aasld-response-to-cochrane-review-on-direct-acting-antivirals-for-hepatitis-c
#7
William G Powderly, Susanna Naggie, Arthur Y Kim, Hugo E Vargas, Raymond T Chung, Anna S Lok
No abstract text is available yet for this article.
July 17, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29019351/hot-news-exosomes-as-new-players-in-hiv-pathogenesis-new-data-from-the-ias-2017
#8
Eva Poveda, Michael L Freeman
Exosomes are nanovesicles that can be released into the extracellular medium by different cell types and are considered an important system of intercellular communication. In some instances, on secretion, exosomes break down and release their content into the extracellular space. Alternatively, intact exosomes can interact with other cells and discharge their content directly into the target cell cytoplasm. Exosomes are rich in endosome-associated proteins (i.e., the tetraspanin family) but also carry different molecules in their lumen including proteins, RNAs (i...
October 11, 2017: AIDS Reviews
https://www.readbyqxmd.com/read/28994443/role-of-raltegravir-in-patients-co-infected-with-hiv-and-hcv-in-the-era-of-direct-antiviral-agents
#9
Lucia Taramasso, Giovanni Cenderello, Niccolò Riccardi, Simone Tunesi, Antonio Di Biagio
Integrase strand transfer inhibitors (INSTIs) are the preferred third agent in first-line antiretroviral therapies. Raltegravir (RAL) was the first INSTI to be approved and used in naïve and experienced patients. Due to its good tolerability and low side effects, RAL has been largely used also in hepatitis co-infected patients. Many years of experience in RAL use now allow literature evidence to be gathered on its safety in HIV/HCV-co-infected patients pre, during and post direct acting agents (DAA) treatment, at all possible stages...
October 10, 2017: New Microbiologica
https://www.readbyqxmd.com/read/28994393/quantitative-measurement-of-hcv-core-antigen-for-management-of-interferon-free-therapy-in-hcv-infected-patients
#10
Mariusz Łucejko, Robert Flisiak
BACKGROUND: According to current recommendations diagnosis and management of HCV infection need detection and quantification of nucleic acids. In the era of direct acting antivirals (DAA) it is essential to develop inexpensive and simple method replacing polymerase chain reaction. Since there is no available data on HCV core antigen (HCVcAg) versus HCV RNA kinetics in the early phase of treatment with DAA, we carried out this study to evaluate possible application of HCVcAg quantitative measurement for management of HCV infection...
October 10, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28992878/peginterferon-alfa-2a-for-the-treatment-of-chronic-hepatitis-c-in-the-era-of-direct-acting-antivirals
#11
REVIEW
Yan Huang, Ming-Hui Li, Min Hou, Yao Xie
BACKGROUND: The availability of novel direct-acting antivirals (DAAs) represents a new era of curative hepatitis C virus (HCV) treatment, with over 95% of patients infected with HCV genotype 1 achieving sustained virological response (SVR). Nevertheless, the majority of patients globally are unable to access these treatments because of cost and infrastructure constraints and, thus, remain untreated and uncured. DATA SOURCE: Relevant articles of peginterferon (PegIFN)-based treatments in HCV and sofosbuvir-based treatments, simeprevir, daclatasvir/asunaprevir, ritonavir-boosted paritaprevir/ombitasvir/dasabuvir, and grazoprevir/elbasvir, were searched in PubMed database, including general population and special population...
October 15, 2017: Hepatobiliary & Pancreatic Diseases International: HBPD INT
https://www.readbyqxmd.com/read/28991836/direct-acting-antiviral-treatment-selection-in-a-child-with-hepatitis-c-virus-infection-and-compensated-cirrhosis
#12
Ignacio Ros, María Baranguan, Ruth García-Romero, Eduardo Ubalde
No abstract text is available yet for this article.
October 6, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/28987254/primer-on-hepatitis-c-virus-resistance-to-direct-acting-antiviral-treatment-a-practical-approach-for-the-treating-physician
#13
REVIEW
Ilan S Weisberg, Ira M Jacobson
Treatment of hepatitis C virus has been vastly transformed by the arrival of all-oral, interferon-free, direct-acting antiviral regimens. Despite the high rate of success with these agents, a small portion of treated patients fail therapy and the emergence of viral resistance is the most common cause of treatment failure. Given the error-prone hepatitis C virus polymerase, baseline resistance-associated substitutions (RASs) may be present before direct-acting antiviral exposure. Clinicians need to understand the role of baseline RAS testing and the settings and manner in which the treatment regimens need to be customized based on the presence of RASs...
November 2017: Clinics in Liver Disease
https://www.readbyqxmd.com/read/28986139/restrictions-for-reimbursement-of-interferon-free-direct-acting-antiviral-drugs-for-hcv-infection-in-europe
#14
Alison D Marshall, Evan B Cunningham, Stine Nielsen, Alessio Aghemo, Hannu Alho, Markus Backmund, Philip Bruggmann, Olav Dalgard, Carole Seguin-Devaux, Robert Flisiak, Graham R Foster, Liana Gheorghe, David Goldberg, Ioannis Goulis, Matthew Hickman, Patrick Hoffmann, Ligita Jancorienė, Peter Jarcuska, Martin Kåberg, Leondios G Kostrikis, Mihály Makara, Matti Maimets, Rui Tato Marinho, Mojca Matičič, Suzanne Norris, Sigurður Ólafsson, Anne Øvrehus, Jean-Michel Pawlotsky, James Pocock, Geert Robaeys, Carlos Roncero, Marieta Simonova, Jan Sperl, Michele Tait, Ieva Tolmane, Stefan Tomaselli, Marc van der Valk, Adriana Vince, Gregory J Dore, Jeffrey V Lazarus, Jason Grebely
All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or more, represent a major clinical advance. However, the high list price of DAAs has led many governments to restrict their reimbursement. We reviewed the availability of, and national criteria for, interferon-free DAA reimbursement among countries in the European Union and European Economic Area, and Switzerland. Reimbursement documentation was reviewed between Nov 18, 2016, and Aug 1, 2017. Primary outcomes were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions...
October 3, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28984238/manipulation-of-both-virus-and-cell-specific-factors-is-required-for-robust-transient-replication-of-a-hepatitis-c-virus-genotype-3a-sub-genomic-replicon
#15
Lorna Kelly, Anjna Badhan, Grace C Roberts, Jean Lutamyo Mbisa, Mark Harris
Hepatitis C virus (HCV) genotype (GT) 3 is the second most prevalent of the seven HCV genotypes and exhibits the greatest resistance to the highly potent, direct-acting antivirals (DAAs) that are currently in use. Previously a stable cell line harbouring the S52 GT3 sub-genomic replicon (SGR) was established, but this SGR was unable to robustly replicate transiently. As transient SGRs are a critical tool in the development of DAAs, and in the study of viral resistance, we sought to establish a transient SGR system based on S52...
October 6, 2017: Journal of General Virology
https://www.readbyqxmd.com/read/28984012/sustained-virological-response-to-ombitasvir-paritaprevir-ritonavir-and-dasabuvir-treatment-for-hepatitis-c-real-world-data-from-a-large-healthcare-provider
#16
Clara Weil, Darshan Mehta, Gideon Koren, Brett Pinsky, Jennifer C Samp, Gabriel Chodick, Varda Shalev
Treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin (OPrD±RBV) was the first interferon-free direct-acting antiviral for hepatitis C virus (HCV) introduced to Israel's national basket of health services in February 2015. Patients with HCV genotype 1 (GT1) and advanced fibrosis (F3-F4) were eligible for treatment in 2015. This study aims to characterize patients initiating OPrD± RBV and assess sustained virological response (SVR). A retrospective cohort study was performed using the database of Maccabi Healthcare Services (MHS), a 2-million-member health plan in Israel...
October 6, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28981632/a-compendium-of-small-molecule-direct-acting-and-host-targeting-inhibitors-as-therapies-against-alphaviruses
#17
Kuan-Chieh Ching, Lisa F P Ng, Christina L L Chai
Alphaviruses were amongst the first arboviruses to be isolated, characterized and assigned a taxonomic status. They are globally widespread, infecting a large variety of terrestrial animals, birds, insects and even fish. Moreover, they are capable of surviving and circulating in both sylvatic and urban environments, causing considerable human morbidity and mortality. The re-emergence of Chikungunya virus (CHIKV) in almost every part of the world has caused alarm to many health agencies throughout the world...
July 21, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28981513/real-life-results-of-sofosbuvir-based-therapy-in-chronic-hepatitis-c-na%C3%A3-ve-and-experienced-patients-in-egypt
#18
Ahmed Nagaty, Ekram W Abd El-Wahab
BACKGROUND: More than ten million Egyptians are infected with HCV. Every one of them is going to infect about three to four persons every year. Treating those patients is a matter of national security. A dramatic improvement in hepatitis C virus (HCV) infection treatment was achieved in the last five years. A new era of direct-acting antivirals is now dawning in Egypt. OBJECTIVE(S): We share in this report our clinical experience in treating chronic HCV Egyptian patients with Sofosbuvir based regimens to evaluate its safety and efficacy on real life practical ground...
2017: PloS One
https://www.readbyqxmd.com/read/28980064/anti-hcv-treatment-with-ombitasvir-paritaprevir-ritonavir%C3%A2-%C3%A2-dasabuvir-is-associated-with-increased-bile-acid-levels-and-pruritus
#19
Rudolf E Stauber, Günter Fauler, Florian Rainer, Bettina Leber, Andreas Posch, Andrea Streit, Walter Spindelboeck, Vanessa Stadlbauer, Harald H Kessler, Harald Mangge
BACKGROUND: Direct acting antiviral (DAA)-based treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir (OBV/PTV/r ± DSV) is highly effective in HCV genotype 1 or 4 infection and well-tolerated with only few side effects. However, pruritus has been observed in several trials in up to 20% of patients and seems to be unique for this DAA combination. OBJECTIVES: The aim of this preliminary study was to investigate the effect of OBV/PTV/r ± DSV on bile acid levels and to correlate them to the emergence of pruritus during treatment...
October 4, 2017: Wiener Klinische Wochenschrift
https://www.readbyqxmd.com/read/28973196/curing-hepatitis-c-virus-infection-best-practices-from-the-u-s-department-of-veterans-affairs
#20
Pamela S Belperio, Maggie Chartier, David B Ross, Poonam Alaigh, David Shulkin
The U.S. Department of Veterans Affairs (VA) is the nation's largest care provider for hepatitis C virus (HCV)-infected patients and is uniquely suited to inform national efforts to eliminate HCV. An extensive array of delivery of services, policy guidance, outreach efforts, and funding has broadened the reach and capacity of the VA to deliver direct-acting antiviral (DAA) HCV therapy, supported by an infrastructure to effectively implement change and informed by extensive population health data analysis. The VA has treated more than 92 000 HCV-infected veterans since all-oral DAAs became available in January 2014, with cure rates exceeding 90%; only 51 000 veterans in VA care are known to remain potentially eligible for treatment...
October 3, 2017: Annals of Internal Medicine
keyword
keyword
70557
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"